Search Results

BioMed Diagnostics to Attend VMX 2024

BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024.

January 9, 2024

·

3 min read

Biotech Bay

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mainz Biomed N.V. will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

March 18, 2024

·

5 min read

Biotech Bay

Mainz Biomed Reports Results of 2024 Annual General Meeting

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general meeting on Friday, May 31, 2024 in Amsterdam, The Netherlands.

May 31, 2024

·

5 min read

Drug Development

BioMed X Start Collaboration in Autoimmunity Research with Servier

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

June 26, 2024

·

3 min read

Press Releases

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

November 7, 2024

·

4 min read

Business

Mainz Biomed Reports Full Year 2023 Financial Results

Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, announced financial results for the fiscal year ended December 31, 2023.

April 9, 2024

·

8 min read

Business

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.

May 13, 2024

·

13 min read

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and online.

June 3, 2024

·

7 min read

Biotech Bay

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

May 28, 2024

·

5 min read

Press Releases

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

November 14, 2024

·

3 min read